REGULATORY

Deregulation Panel Prods Govt to Fuel SaMD Development

June 3, 2021

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

The government’s Regulatory Reform Promotion Council presented a recommendation to Prime Minister Yoshihide Suga on June 1, urging the government to facilitate management of clinical trials and promote the development of software as a medical device (SaMD). After receiving an…

To read the full story

Regulatory Reform Panel Urges Better Trial Environment, SaMD Review
December 24, 2021
Industry Calls for Simplifying Regulatory Process for SaMD
October 26, 2021

REGULATORY

MHLW Orders Label Revisions for Aspirin, CAR-T Therapies, and Other Drugs
January 14, 2026
Japan to Stick with 7 New Drug Approval Rounds a Year
January 14, 2026
MHLW to Set Up Expert Panel on Using Disease Registries in Drug Development
January 13, 2026
Chuikyo Moves to Allow Special Mixed-Billing for Santen’s Myopia Drug
January 13, 2026
Japan Panel to Review AbbVie’s Aquipta, Ipsen’s Sohonos on January 23
January 13, 2026

Chuikyo Debate on FY2026 Drug Pricing Reform

Gist of FY2026 Drug Pricing Reform Outline

The Central Social Insurance Medical Council, a key Japanese reimbursement policy panel better known as Chuikyo, approved an outline of…

COMMENTARY

Wave of “World Firsts” Looms as 47 New Drug Candidates Line Up for 2026

By Shinya Sato

As many as 47 new drug candidates are expected to win approval or secure NHI price listing in Japan in…

COLUMN

AI: Your New HR BFF (Not Your Replacement!)

By Philip Carrigan

Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…